Racial and regional differences in rates of invasive pneumococcal disease

Pediatrics

Volumn 136, Issue 5, 2015, Pages e1186-e1194

  De St Maurice, Annabelle ^a   Grijalva, Carlos G ^a   Fonnesbeck, Christopher ^b   Schaffner, William ^a   Halasa, Natasha B ^a  

^a Department of Pediatrics ^*  (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ADOLESCENT; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CHILDHOOD DISEASE; FEMALE; GEOGRAPHIC AND GEOLOGICAL PHENOMENA; GROUPS BY AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; OUTPATIENT; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RACE DIFFERENCE; REGIONAL DIFFERENCE; SEROTYPE; UNITED STATES; VACCINATION; ETHNOLOGY; PNEUMOCOCCAL INFECTIONS; TENNESSEE;

FEMALE; HUMANS; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; TENNESSEE; VACCINES, CONJUGATE;

EID: 84947244329     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2015-1773     Document Type: Article

References (37)

1. Castelblanco RL, Lee M, Hasbun R. Epidemiology of bacterial meningitis in the USA from 1997 to 2010: a population-based observational study. Lancet Infect Dis. 2014;14(9):813-819
2. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007; 369(9568):1179-1186
3. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295(14):1668-1674
4. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3): 244-256
5. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010; 201(1):32-41
6. Hampton LM, Farley MM, Schaffner W, et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis. 2012;205(3):401-411
7. O'Brien KL, Levine OS. Effectiveness of pneumococcal conjugate vaccine. Lancet. 2006;368(9546):1469-1470
8. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197(7):1016-1027
9. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010; 59(9):258-261
10. Centers for Disease Control and Prevention. Active Bacterial Core surveillance. Methodology-surveillance population. www.cdc.gov/abcs/methodology/surv-pop.html. Accessed May 30, 2014
11. Halasa N, Grijalva CG, Arbogast PG, et al. Near complete elimination of the seven valent pneumococcal conjugate vaccine serotypes in Tennessee. Pediatric Inf Dis J. 2013;32(6):604-609
12. Rosen JB, Thomas AR, Lexau CA, et al; CDC Emerging Infections Program Network. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis. 2011;53(2):137-143
13. Flannery B, Schrag S, Bennett NM, et al; Active Bacterial Core Surveillance/Emerging Infections Program Network. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004; 291(18):2197-2203
14. Talbot TR, Poehling KA, Hartert TV, et al. Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine. Pediatr Infect Dis J. 2004;23(8):726-731
15. Wortham JM, Zell ER, Pondo T, et al. Racial disparities in invasive Streptococcus pneumoniae infections, 1998-2009. Clin Infect Dis. 2014;58(9): 1250-1257
16. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32(3):203-207
17. Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014; 134(2):210-217
18. Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman K.P. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387-394
19. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301-309
20. Perz JF, Craig AS, Jorgensen DM, Hall S, Schaffner W. Evaluation of innovative surveillance for drug-resistant Streptococcus pneumoniae. Am J Epidemiol. 2001;154(11):1000-1005
21. Perz JF, Craig AS, Coffey CS, et al. Changes in antibiotic prescribing for children after a community-wide campaign. JAMA. 2002;287(23):3103-3109
22. Poehling KA, Talbot HK, Williams JV, et al. Impact of a school-based influenza immunization program on disease burden: comparison of two Tennessee counties. Vaccine. 2009;27(20):2695-2700
23. Sloan CD, Gebretsadik T, Wu P, Carroll KN, Mitchel EF, Hartert TV. Spatiotemporal patterns of infant bronchiolitis in a Tennessee Medicaid population. Spat Spatio-Temporal Epidemiol. 2013;6:17-23
24. Acute respiratory infections: the forgotten pandemic. Bull World Health Organ. 1998;76(1):101-103, 105-107
25. United States Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States, states, counties, and Puerto Rico Commonwealth and Municipios: April 1, 2010 to July 1, 2013. Available at: http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?src=bkmk
26. Schuchat A, Hilger T, Zell E, et al; Active Bacterial Core Surveillance Team of the Emerging Infections Program Network. Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis. 2001;7(1):92-99
27. Institute UoWPH. County Health Rankings 2013
28. Talbot TR, Poehling KA, Hartert TV, et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2004;39(5):641-648
29. StataCorp. Stata 13 Base Reference Manual. College Station, TX: Stata Press; 2015
30. Pelton SI, Huot H, Finkelstein JA, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26(6):468-472
31. Levy C, Varon E, Picard C, et al. Trends of pneumococcal meningitis in children after introduction of the 13-valent pneumococcal conjugate vaccine in France. Pediatr Infect Dis J. 2014;33(12): 1216-1221
32. Results of the 2013 Immunization Status Survey of 24-Month-Old Children in Tennessee: Tennessee Immunization Program. Tennessee Department of Health; 2013
33. Smith MD, Stuart J, Andrews NJ, Telfer Brunton WA, Cartwright KA. Invasive pneumococcal infection in South and West England. Epidemiol Infect. 1998; 120(2):117-123
34. Stoll ML, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. Arch Pediatr Adolesc Med. 2004;158(7): 671-675
35. Sard B, Bailey MC, Vinci R. An analysis of pediatric blood cultures in the post-pneumococcal conjugate vaccine era in a community hospital emergency department. Pediatr Emerg Care. 2006; 22(5):295-300
36. Lee GM, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. Pediatrics. 2001;108(4):835-844
37. Hicks LA, Chien YW, Taylor TH Jr, Haber M, Klugman KP; Active Bacterial Core Surveillance (ABCs) Team. Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis. 2011;53(7): 631-639